AKR1B10 and hepatocellular carcinoma: However, in the current state of research, AKR1B10 has not been widely used as a predictive test for HCC compared to AFP in clinical applications, and further comprehensive studies or large randomized controlled multicenter trials are required to delve deeper into the clinical significance of AKR1B10 in patients with HCC.